Cariprazine (Vraylar)


FDA Approved Indications:

  • Treatment of schizophrenia
  • Acute treatment of manic or mixed episodes associated with bipolar I disorder

Prior authorization criteria:

  • Diagnosis of schizophrenia or bipolar I disorder
  • 18 years of age or older
  • Patient has tried and failed at least 2 preferred atypical antipsychotics (e.g., risperidone, quetiapine, olanzapine, ziprasidone, aripiprazole)


  • Once daily (maximum dose is 6 mg/day)
    • Schizophrenia: starting dose 1.5mg/day, Recommended dose is 1.5 mg to 6 mg/day
    • Bipolar mania: starting dose 1.5mg/day, Recommended dose is 3 mg to 6 mg/day
  • Reduce Vraylar dosage if used with a strong CYP3A4 inhibitor
  • Concomitant use of Vraylar with a CYP3A4 inducer is not recommended


  • 1 year

Last review date: June 27, 2017

WHA is closely monitoring the Coronavirus Disease 2019 (COVID-19). Learn more about COVID-19.